Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

Summary: Background: The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-d...

Full description

Bibliographic Details
Main Authors: Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:EClinicalMedicine
Subjects:
Multiple myeloma
Elderly
Daratumumab
Ixazomib
Intermediate-fit
IMWG frailty index
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023003449

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023003449

Similar Items